TOMDF Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EST
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume56.82K
Average Volume (3M)N/A
Market Cap
$1.41K
Enterprise Value$38.33M
Total Cash (Recent Filing)$34.00K
Total Debt (Recent Filing)$38.35M
Price to Earnings (P/E)―
Beta25.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,408,127,200
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.36
Price to Sales (P/S)1.65
P/FCF Ratio-4.55
Enterprise Value/Market Cap27.22K
Enterprise Value/Revenue4.98
Enterprise Value/Gross Profit9.39
Enterprise Value/Ebitda-5.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TOMDF FAQ
What was Todos Medical Ltd.’s price range in the past 12 months?
Currently, no data Available
What is Todos Medical Ltd.’s market cap?
Todos Medical Ltd.’s market cap is $1.41K.
When is Todos Medical Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Todos Medical Ltd.’s earnings last quarter?
Currently, no data Available
Is Todos Medical Ltd. overvalued?
According to Wall Street analysts Todos Medical Ltd.’s price is currently Overvalued.
Does Todos Medical Ltd. pay dividends?
Todos Medical Ltd. does not currently pay dividends.
What is Todos Medical Ltd.’s EPS estimate?
Todos Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Todos Medical Ltd. have?
Todos Medical Ltd. has 1,408,127,200 shares outstanding.
What happened to Todos Medical Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Todos Medical Ltd.?
Currently, no hedge funds are holding shares in TOMDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Todos Medical Ltd.
Todos Medical Ltd. operates as an in vitro diagnostics company, concentrating on the creation and commercialization of blood tests for the early detection of cancer and Alzheimer's disease, primarily serving the United States market. The company's innovative approaches to cancer diagnostics include the Total Biochemical Infrared Analysis (TBIA), a proprietary screening technology that uses peripheral blood spectroscopy to investigate cancer's effects on the immune system. Another key offering is the Lymphocyte Proliferation Test (LPT), a diagnostic blood assay designed to assess how peripheral blood lymphocytes and monocytes react to exogenous mitogenic stimulation, which induces cell cycle entry. Their cancer product lineup includes TM-B1 and TM-B2 for breast cancer screening, alongside the TMC blood test for diagnosing colon cancer. Beyond oncology, Todos Medical is also actively developing blood-based tests for identifying neurodegenerative conditions, notably Alzheimer's disease. In addition to its diagnostic portfolio, the company markets Tollovid, a dietary supplement acting as a 3CL protease inhibitor, formulated to bolster a healthy immune response against common coronaviruses. Furthermore, Tollovir, an antiviral treatment for Covid-19, is currently progressing through Phase 2 clinical trials. Todos Medical Ltd. engages in strategic alliances, including a collaboration with Integrated Health LLC, and has various agreements in place for developing SARS-nCoV-2 screening tests and distributing specific COVID-19 test kits. The company was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
―
Scinai Immunotherapeutics
―
PainReform
―
Bluejay Diagnostics
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors